Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing

Autor: Rivoltini L, Marina Radrizzani, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Mp, Colombo, Parmiani G

Publikováno v: Europe PubMed Central

Tumor cells have been shown recently to escape immune recognition by developing resistance to Fas-mediated apoptosis and acquiring expression of Fas ligand (FasL) molecule that they may use for eliminating activated Fas+ lymphocytes. In this study, w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f00a61680d928b11858ac3bf75861b6
https://pubmed.ncbi.nlm.nih.gov/9686582

Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice

Autor: Sfondrini L, Monica Rodolfo, Singh M, Mp, Colombo, Mi, Colnaghi, Ménard S, Balsari A

Publikováno v: Scopus-Elsevier
Europe PubMed Central

An approach to stimulating an immune response against tumors is to transduce tumor cells with bacterial genes, which represent a "danger signal" and can induce a wide immune response. Mycobacterium tuberculosis genes and their encoded proteins play a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::46ef8718fcfeb367394b0c7ffab9972b
http://www.scopus.com/inward/record.url?eid=2-s2.0-0034660873&partnerID=MN8TOARS

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.

Autor: G Parmiani¹, C Castelli¹, L Pilla¹, M Santinami², MP Colombo³, L Rivoltini¹

Publikováno v: Annals of Oncology. Feb2007, Vol. 18 Issue 2, p226-232. 7p.

Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer.

Autor: Sulsenti R; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Scialpi GB; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Frossi B; Immunology Section, Department of Medicine, University of Udine, Udine, Italy., Botti L; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Ferri R; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Tripodi I; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Piva A; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Sangaletti S; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Pernici D; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Cancila V; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy., Romeo F; Dipartimento di Onologia Sperimentale, European Institute of Oncology IRCCS, Milan, Italy., Chiodoni C; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Lecis D; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Bianchi F; Microenvironment and Biomarkers in Solid tumors Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Fischetti I; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Enriquez C; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Crivelli F; Oncology-Hematology Unit, ASST Valle Olona, Busto Arsizio, Italy., Bregni M; Oncology-Hematology Unit, ASST Valle Olona, Busto Arsizio, Italy., Renne G; Uropathology and Intraoperative Diagnostic Division, European Institute of Oncology IRCCS, Milan, Italy., Pece S; Dipartimento di Onologia Sperimentale, European Institute of Oncology IRCCS, Milan, Italy., Tripodo C; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy., Pucillo CE; Immunology Section, Department of Medicine, University of Udine, Udine, Italy., Colombo MP; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Jachetti E; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2024 Sep 03; Vol. 12 (9), pp. 1147-1169.

Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.

Autor: Cancila V; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy., Morello G; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy., Bertolazzi G; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.; Department of Economics, Business, and Statistics, University of Palermo, Palermo, Italy., Chan AS; Cancer Science Institute of Singapore, National University of Singapore, Singapore., Bastianello G; IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy., Paysan D; Laboratory for Nanoscale Biology, Paul Scherrer Institute, Villigen, Switzerland.; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland., Jaynes PW; Cancer Science Institute of Singapore, National University of Singapore, Singapore., Schiavoni G; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy., Mattei F; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy., Piconese S; Department of Internal Clinical Sciences, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.; IRCCS Fondazione Santa Lucia, Unità di Neuroimmunologia, Rome, Italy.; Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy., Revuelta MV; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York., Noto F; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy., De Ninno A; Institute for Photonics and Nanotechnologies, Italian National Research Council, Rome, Italy., Cammarata I; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; Neuroimmunology Unit, IRCCS Fondazione Santa Lucia, Rome, Italy., Pagni F; Department of Medicine and Surgery, Pathology, IRCCS Fondazione San Gerardo dei Tintori, University of Milano-Bicocca, Italy., Venkatachalapathy S; Laboratory for Nanoscale Biology, Paul Scherrer Institute, Villigen, Switzerland., Sangaletti S; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Di Napoli A; Pathology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy., Vacca D; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy., Lonardi S; Pathology Unit, ASST Spedali Civili di Brescia, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy., Lorenzi L; Pathology Unit, ASST Spedali Civili di Brescia, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy., Ferreri AJM; Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Belmonte B; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy., Varano G; IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy., Colombo MP; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Bicciato S; Department of Molecular Medicine, University of Padova, Padova, Italy., Inghirami G; Pathology and Laboratory Medicine Department, Weill Cornell Medicine and New York-Presbyterian Hospital, New York., Cerchietti L; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York., Ponzoni M; Vita-Salute San Raffaele University, Milan, Italy.; Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Zappasodi R; Department of Medicine, Weill Cornell, New York, NY, USA., Facchetti F; Pathology Unit, ASST Spedali Civili di Brescia, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy., Foiani M; IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy., Casola S; IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy., Jeyasekharan AD; Cancer Science Institute of Singapore, National University of Singapore, Singapore.; Department of Haematology-Oncology, National University Health System, Singapore, Singapore.; NUS Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Tripodo C; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.; IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.

Publikováno v: Research square [Res Sq] 2024 Mar 18. Date of Electronic Publication: 2024 Mar 18.